EPO and Huntington disease: Two groups of adult, chronic, and  stable HD patients were enrolled. Group 1 was already under maintenance treatment with IV  recombinant human EPO (rhEPO) thrice weekly. Group 2 included ESRD patients not previously treated with rhEPO. Both groups were subjected to IV and SC rhEPO administration at different dosages – 50 U/kg for group 1 and 150 U/kg for group 2. Pharmacokinetic studies were then carried out using serum analytics.